Filing summary
Issuer and period: The supplied filing is Oculus Innovative Sciences, Inc.’s Form 10-K for the fiscal year ended March 31, 2016, not a filing for Sonoma Pharmaceuticals, Inc. or a standalone 2015 fourth quarter. The filing reports annual results and does not provide a clear standalone Q4 financial summary.
Business context
Oculus described itself as a specialty pharmaceutical company focused on medical dermatology and advanced tissue care. Products included Celacyn, Ceramax, Alevicyn, Mondoxyne and Microcyn-based products. The company sold in the U.S. and internationally, with 67% of FY2016 product-related revenue, including license fees and royalties, generated outside the U.S.
Financial performance and liquidity
| Metric | FY ended Mar. 31, 2016 | FY ended Mar. 31, 2015 |
|---|---|---|
| Total revenue | $15.084 million | $13.854 million |
| Gross profit / margin | $7.210 million / 48% | $7.288 million / 53% |
| Operating expenses | $17.362 million | $13.947 million |
| Operating loss | $10.152 million | $6.659 million |
| Net loss | $10.162 million | $8.203 million |
| Net loss per share, basic and diluted | $0.62 | $0.85 |
| Cash used in operating activities | $8.746 million | $6.694 million |
| Cash and cash equivalents at year-end | $7.469 million | $6.136 million |
| Working capital at year-end | $9.337 million | $7.066 million |
Product revenue rose 31% to $13.042 million; product gross margin improved to 46% from 41%. These gains were offset by product license fees and royalties falling 68% to $981,000, primarily after the Innovacyn agreement ended and Sanfer upfront-fee amortization declined. Service revenue increased to $1.061 million from $859,000. SG&A rose 25% to $15.556 million, driven mainly by U.S. dermatology sales-force and launch costs.
At March 31, 2016, total liabilities were $3.663 million, including $114,000 of current debt; the filing lists $691,000 of operating lease commitments. Financing cash inflows included $2.994 million net from a March 2016 offering and $3.150 million net from at-the-market stock sales. Cash balances also benefited from $4.538 million in proceeds from selling the remaining Pulmatrix shares. The company reported no off-balance-sheet arrangements.
Changes, outlook and risks
- U.S. product revenue increased 121% to $4.371 million, attributed mainly to dermatology sales; Europe and Rest of World product revenue rose 27% to $3.706 million. Latin American product revenue declined 2% in U.S. dollars, while local-currency sales increased 17%; management cited a 19% peso decline.
- Management planned to expand the U.S. sales force, develop and launch dermatology products, and pursue pharmaceutical products. Lasercyn had received U.S. 510(k) clearance in 2016; management said it intended to launch it within nine months. SG&A was expected to rise as the sales force expanded. These are plans, not assured outcomes.
- The company expected continued losses and said it might need additional capital. Management had no committed new financing and warned that failure to raise funds could force cost reductions and delay commercialization. The auditor’s report included an explanatory going-concern paragraph stating that these conditions raised substantial doubt about the company’s ability to continue as a going concern.
- Key risks included customer and receivables concentration, international and foreign-exchange exposure, dependence on distributors and partners, regulatory and clinical-trial uncertainty, competition, and potential dilution from equity and warrant issuance. One customer accounted for 40% of net revenue; a separate customer represented 33% of net receivables.
- FY2015 included a $4.650 million impairment loss on the Ruthigen investment and a $3.164 million gain from derivative-liability remeasurement; neither amount recurred in FY2016. The company sold its remaining Pulmatrix shares in FY2016.
- The board approved a 1-for-5 reverse stock split on June 2, 2016, after fiscal year-end, with an effective date stated as June 24, 2016. The filing also notes NASDAQ minimum-bid-price concerns.
Important facts to verify
- Confirm issuer identity and requested period: the supplied document is Oculus’s FY2016 10-K, not Sonoma’s 10-K or a standalone 2015 Q4 filing.
- Verify subsequent liquidity, financing needs and progress against the going-concern plan.
- Check whether the planned Lasercyn launch and other commercialization targets were achieved, and whether sales growth translated into improved operating performance.
- Review customer concentration, Sanfer-related receivables and the effect of currency movements on international revenue and collections.
- Confirm the reverse split’s completion and subsequent share count, and assess potential dilution from outstanding warrants and options.